We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Provepharm Sign Three New Distribution Agreements in Europe

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Provepharm Sign Three New Distribution Agreements in Europe"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Provepharm has announced that it has extended its international distribution network by signing new agreements covering eight additional European countries.

Provepharm has recently concluded one licensing and distribution agreement with NordMedica for the distribution of its product in the five Scandinavian countries - Norway, Sweden, Finland, Denmark and Iceland - and has also signed agreements with A VIPharma in Greece and Cyprus, and with Fresenius Kabi Portugal for the Portuguese market.

As the product is already commercialized in France, the United Kingdom and Ireland, these new agreements mean that it will now be available to one-third of Europeans (more than 175 million people).

Following the centralized European regulatory marketing approval granted for its drug, these agreements represent another important milestone in the development of Provepharm’s distribution network in Europe.

“The expansion of the Provepharm distribution network throughout Europe is an important step to enable Provepharm to respond to a medical need that is currently unmet or poorly met at a world level, by commercializing a drug that complies with the most recent quality and regulatory requirements,” said Christian Neuman, Provepharm’s director of business, development and licensing.

“The European expansion is part of a wider international strategy for our distribution network. This began with a major partnership concluded with the Japanese company Daiichi Sankyo in 2011,” said Michel Feraud, president of Provepharm.

Feraud continued, “Having recently created our American subsidiary, Provepharm Inc., in New York state, the next part of our strategy is to develop our distribution network throughout North America.”

In order to anticipate the rolling-out of this strategy to other regions of the world and its extension to new therapeutic applications, Provepharm has also strengthened its management in France by hiring five new executives.

Three have been recruited by the R&D department as project managers in the areas of regulatory affairs, chemistry and galenical formulation, while another has joined the marketing department as project manager.

A new director of supply chain post has also been created to ensure full control over the procurement of active substances and finished products supplied by CMOs.